TY - JOUR
T1 - Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan
AU - Ho, Ya Chi
AU - Shih, Tiffany T.F.
AU - Lin, Yu Hui
AU - Hsiao, Chin Fu
AU - Chen, Mao Yuan
AU - Hsieh, Szu Min
AU - Sheng, Wang Huei
AU - Sun, Hsin Yun
AU - Hung, Chien Ching
AU - Chang, Shan Chwen
PY - 2007/12/4
Y1 - 2007/12/4
N2 - Osteonecrosis, a disabling complication associated with antiretroviral therapy (ART) and human immunodeficiency virus (HM infection, has rarely been reported in an Asian population. After an observation of 3,250 person-years (PY), 11 of 967 (1.1%) HIV-infected patients at a median age of 34 years developed osteonecrosis involving the hip joints (incidence, 3.4 per 1,000 PY). Their median CD4+ lymphocyte count had increased from 35 cells/μL at the diagnosis of IRV infection to 297 cells/μL at the diagnosis of osteonecrosis. The crude rate of osteonecrosis increased from 0% in patients without exposure to ART to 2.6 and 1.7% in patients with exposure to nucleoside reverse transcriptase inhibitors (NRTIs) and who had undergone highly active antiretroviral therapy (HAART) for 5 years or longer, respectively (P = 0.18 and 0.09, respectively). Among the patients receiving HAART, the estimated incidence of osteonecrosis was 4.2 per 1,000 PY. Patients with osteonecrosis had a longer duration of exposure to NRTls (1,641 versus 1,264 days, P = 0.26) and to HAART (1,603 versus 1,251 days, P = 0.42), a higher serum triglyceride (median, 1,130 versus 351 mg/dl; P = 0.09), and a higher proportion of lipodystrophy (81.8 versus 15.0%, P < 0.0001). Our report suggests that osteonecrosis is a rare complication in HIV-infected patients with prolonged exposure to ART with resultant metabolic complications.
AB - Osteonecrosis, a disabling complication associated with antiretroviral therapy (ART) and human immunodeficiency virus (HM infection, has rarely been reported in an Asian population. After an observation of 3,250 person-years (PY), 11 of 967 (1.1%) HIV-infected patients at a median age of 34 years developed osteonecrosis involving the hip joints (incidence, 3.4 per 1,000 PY). Their median CD4+ lymphocyte count had increased from 35 cells/μL at the diagnosis of IRV infection to 297 cells/μL at the diagnosis of osteonecrosis. The crude rate of osteonecrosis increased from 0% in patients without exposure to ART to 2.6 and 1.7% in patients with exposure to nucleoside reverse transcriptase inhibitors (NRTIs) and who had undergone highly active antiretroviral therapy (HAART) for 5 years or longer, respectively (P = 0.18 and 0.09, respectively). Among the patients receiving HAART, the estimated incidence of osteonecrosis was 4.2 per 1,000 PY. Patients with osteonecrosis had a longer duration of exposure to NRTls (1,641 versus 1,264 days, P = 0.26) and to HAART (1,603 versus 1,251 days, P = 0.42), a higher serum triglyceride (median, 1,130 versus 351 mg/dl; P = 0.09), and a higher proportion of lipodystrophy (81.8 versus 15.0%, P < 0.0001). Our report suggests that osteonecrosis is a rare complication in HIV-infected patients with prolonged exposure to ART with resultant metabolic complications.
UR - http://www.scopus.com/inward/record.url?scp=36549038618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36549038618&partnerID=8YFLogxK
M3 - Article
C2 - 18032839
AN - SCOPUS:36549038618
SN - 1344-6304
VL - 60
SP - 382
EP - 386
JO - Japanese Journal of Infectious Diseases
JF - Japanese Journal of Infectious Diseases
IS - 6
ER -